UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.

Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...